<DOC>
	<DOCNO>NCT01482013</DOCNO>
	<brief_summary>This safety tolerability study investigate effect HPP854 subject mild cognitive impairment diagnosis mild Alzheimer 's disease . The study assess pharmacokinetic pharmacodynamic relationship HPP854 plasma , pharmacodynamic relationship cerebral spinal fluid plasma concentration profile Amyloid-Beta .</brief_summary>
	<brief_title>Safety Study HPP854 Subjects With Mild Cognitive Impairment Diagnosis Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Medical history least 6 month prior screen mild cognitive impairment Mini Mental State Exam ( MMSE ) score 20 26 diagnosis mild Alzheimer 's disease ; Must able swallow dose study medication ; Body Mass Index ( BMI ) 18.0 35.0 ; Subject Project Partner willing participate agree comply study requirement . Blood pressure &gt; 160 mmHg ( systolic ) &gt; 90 mmHg ( diastolic ) ; Received HPP854 previous trial ; Participation another clinical trial involve market investigational drug within 30 day screen final study visit . Current evidence history within last 3 year neurological psychiatric illness could contribute dementia include limited : anxiety , epilepsy , focal brain lesion , Parkinson 's disease , seizure disorder , head injury loss consciousness alcohol substance abuse ; Clinically significant cardiovascular , cerebrovascular disease , diabetic condition , hematologic , renal hepatic , pulmonary , endocrine , neurological , coagulation disorder ; History presence cancer except non melanoma skin cancer . Subjects history prostate cancer stable &gt; 3 yrs active treatment &gt; 3 year prior Screening may consider eligibility ; Use follow medications/therapy 14 day dose Final Visit : anticholinergic , tricyclic antidepressant , lithium , typical atypical antipsychotic medication , anticonvulsant medication , immunosuppressive agent , oral corticosteroid , radiotherapy ; HbA1C &gt; 6.5 % Screening Visit ; Vitamin B12 level &lt; 211 pg/mL Screening Visit ; Any suicidal risk determine CSSRS administer study staff member appropriately certified administration scale ( Baseline/Screening , Phase 1 Study Version ) Screening Visit , Day 6 Day 1 ; A score 15 modify Geriatric Depression Scale ( GDS ) ; A score 5 Hashinski Ischemic Scale ( Rosen modification . Contraindications MRI include : Metallic fragment , clip device brain , eye , spinal canal , etc ; Cardiac pacemaker , insulin pump , neurostimulators , cochlear implant , etc . Contraindications blood CSF sampling , include : Bleeding disorder take anticoagulants/antiplatelet , chronic active infection .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>